$500,000 in 48 Hours: The Handy 2 Shatters Kickstarter Expectations
LONDON, May 30, 2025 /PRNewswire/ -- Ohdoki's latest male adult toy launch is off to a record-breaking start. Just 48 hours after hitting Kickstarter, the new The Handy 2 and The Handy 2 Pro have racked up a staggering $500,000 in pledges, securing their place as the #1 product on Kickstarter on launch day.
The campaign surged past $50,000 in under three minutes, hit $100,000 before the 20-minute mark, and hasn't slowed since. The demand confirms what fans of the original The Handy have been saying for years: no one is pushing the boundaries of pleasure-tech like Ohdoki.
"The response has been overwhelming," said JP Wilhelmsen, CEO at Ohdoki. "This launch wasn't just about a new product — it was a moment of validation. Seeing our community show up with this kind of passion proves the trust they've placed in us. The Handy 2 was built from direct user feedback, and this level of early support tells us we got it right. We're grateful, humbled, and more energized than ever to keep pushing the boundaries of what's possible in interactive pleasure."
Building on the success of the original device - which sold over 200,000 units worldwide - The Handy 2 and The Handy 2 Pro are interactive strokers for men that introduce a suite of powerful upgrades. The devices feature a built-in battery for complete wireless use, a ClickOn system for faster and easier session starts – including for using the popular Fleshlights -, and support for upcoming modular accessories. Inside, a custom next-gen motor delivers more power and torque while reducing noise, making the experience smoother and more discreet.
As with its predecessor, The Handy 2 offers unmatched interactive capabilities, including real-time syncing with flat and VR videos, games, and custom apps. It retains an open API and full access to the world's largest library of synced adult content.
The Handy 2 and Handy 2 Pro are now available for pre-order exclusively on Kickstarter, with early-bird discounts and delivery beginning in August 2025. The retail launch will follow on thehandy.com and Amazon in late 2025 or early 2026.
For more information or to pre-order, visit The Handy 2: The #1 Male Sex Toy, Now Even Better by Ohdoki — Kickstarter .
About Ohdoki
Ohdoki is a cutting-edge pleasure-tech company based in Norway. They developed The Handy, an advanced male interactive stroker with VR capabilities. With a growing online community of over 25,000 members, Ohdoki is committed to breaking taboos and bringing fun and elevated sexual experiences.
Photo - https://mma.prnewswire.com/media/2700326/Handy2_Hero_01.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/500-000-in-48-hours-the-handy-2-shatters-kickstarter-expectations---ohdoki-302469904.html
SOURCE Ohdoki
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
'Dead Girl' fights cancer and more, lives to share her story
May 30—Palliative nurse's notes, Aug. 2, 2019: "Participated in Hospice meeting with patient. Seth (spouse), mother, father, bedside RN. Andrea from Hospice was on speakerphone. Discussed philosophy of Hospice and services they provide. Advised that by accepting Hospice, patients have a terminal diagnosis with less then six months to live. Patient was surprised by this, stating she would not qualify. Gina had several questions regarding cancer diagnosis, stating, 'I don't think I am terminal' and unaware of staging/diagnosis .... Patient continues to repeat she is only 46 years old and would like to continue with a treatment as offered and hopefully start immunotherapy when able. Seth was in agreement and supportive." — Book excerpt WATERTOWN — Eugenia Mancini Horan opens the front door of her parent's home on outer Bradley Street to welcome a visitor, this writer, who tells her that from what he's read about her, she looks amazing. "Your reaction is much like when I go to a new doctor and they open the door and are like, 'I was expecting someone deader,'" she says, laughing. Eugenia ("Gina") has crawled, bled, begged, argued, rejoiced and has been mocked through the ravages of stage 4 cancer. It is simply amazing, a miracle some say, that she is alive and cancer free. She recounts her 2019 cancer journey in the self-published, "The Dead Girl's Guide to Terminal Cancer: A True Tale of Anxiety, Horror & Hope." It's been the number one best seller on Amazon's lung cancer category for several weeks. It's a hardbound 400 pages, the size of a college textbook and its emotional weight vastly outweighs its 2 pounds. Its cover features a deer-in-the headlights-like self-portrait of the author, who has won a slew of awards on the local arts scene for her oil paintings. Readers have called the book darkly humorous and poignant. With its various characters, tragic subplots of her youth, family dynamic and medical notes, its is also novelesque. For the gist of it, Gina summarizes it all in the book's afterward: "There are no heroes in this story, no saviors, no 'Good Doc With a Cure,' coming in for a last-minute save. There is only medical bias, cancer bias, and the notion that a girl who is afraid of the world can't fight like a rabid animal to stay alive." 'Let me live' "My whole story is fighting people to get them to let me live," Gina said in the room of her parents' home, where in 2019, a hospital bed was set up in front of a picture window and where many expected her to meet her demise while battling lung cancer which she said had spread to her trachea, bronchus and small bowel. "Somebody should be treated like they're dead when they are already dead." "It's such a scary diagnosis and we have put such faith in the white lab coat," said Seth, who helped his wife with the book. "I know because we did it. You will cling to anything you are told. That has been the most horrifying, duh! moment during this whole process: to have the curtain pulled back and it's like, these are just people. And people make mistakes. And every one of them made a mistake with her." "When putting out the book, you couldn't think about someone reading it because it's like, 'Here is every bad thing that ever happened to me and people treating me badly.' Would you like to read it? It's embarrassing," Gina said. "But I thought in it, there's got to be something that can help people: look for these red flags, don't just trust. I've been a cancer advocate for five years and now I have two enemies." One of those enemies, she said, is God. "Which sounds harsh, but people pray to God that he's going to cure cancer, so they become inactive." The second: "People implicitly trusting that their doctors have their best health in mind when they come up with cures. No doctor comes up with a cure. It's a list. It's, 'If you have this cancer, in this stage, this is what you get.'" Gina's "Dead Girl's Guide to Terminal Cancer" encapsulates one year, 2019, from when she was diagnosed to when she saved herself, thanks to her desperate pleas to try immunotherapy — specifically Keytruda — a type of immunotherapy that works by blocking a pathway to help prevent cancer cells from hiding. Immunotherapy uses a person's own immune system to fight cancer. Blood and a diagnosis Gina woke up on Christmas morning, 2018, at their home in North Syracuse and thought she had the flu or something. When she coughed, she noticed little flecks of blood on a tissue. As a smoker, she thought it could be normal. "But one night, it was abnormal," she said. "It was nose-bleed-like." She also experienced shortness of breath and a racing heartbeat. Gina said she has had symptoms of anxiety disorder since age 5 and was finally diagnosed with it at age 17. Considered disabled, she has Medicaid. At the medical appointment to address what she was coughing up, she said she was told, 'I think you just got yourself worked up with your anxiety.'" "And I'm like, 'That's powerful. I was torn because I wanted her to say it was nothing, and then when she said it was nothing, it was, 'I can't let it go. Can we run some blood work?' By the time we got home, the phone was ringing. I failed that blood work bad." What followed was a series of tests and scans that wreaked havoc on Gina's anxiety. She was diagnosed with non-small cell lung cancer in mid-February, 2019 at a Syracuse hospital, one of two hospitals in that city which treated her during her year-long ordeal. She doesn't name the hospitals in the book and requested the Syracuse hospitals not be named here. Radiology summary/Feb. 15, 2019: Impression: Right apical lobulated mass is seen. Right hilar lymph nodes are seen possibly exerting a mass effect on the right main bronchus. No pulmonary arterial embolus is identified." In the top portion of her uppermost lobe, there was an unusual mass. Also, some lymph nodes had grown large enough to restrict airflow through her right main bronchus. Surgery, which didn't make sense to Gina, was recommended. "How was taking out two lobes of my lungs — to remove the origin tumor that wasn't causing any issue — going to help with the mass that was actually threatening my life? Was this just busy work?" she writes in the book. A cancer diagnosis can bring thoughts of chemotherapy. That wasn't originally in the cards for Gina, a "card-carrying emetrophopbic." Emetophobia is the fear of vomiting and can be triggered just by seeing someone else being sick. As an alternative, Gina and Seth tried highly concentrated cannabis oil. Meanwhile, Gina's parents, Eugene and Clorise Mancini, urged her to come home to Watertown as her health declined. Gina and Seth moved there in May, 2019. "The drive there filled me with both anxiety and salvation," Gina wrote in the book. "Seth figured out how to get the oxygen compressor to work in the car." Gina could not walk to the front door, and it marked the first of hundreds of times that Seth would carry his wife. This year, on the sixth-year anniversary of her diagnosis, Gina, on Facebook, paid tribute to Seth, who she married in 2006: "My husband dropped everything when I got sick to be my caregiver. For five months everywhere I needed to go, he carried me because I couldn't walk. Bedpans? Did that. Suctioning out my trach? That too. Butt wiping? Yup, even that. Yet, most days, we still laughed because we were still us." Gina entered Walker Center for Cancer Care at Samaritan Medical Center, Watertown, for the first time on June 5, 2019, where she would stay as an inpatient for a week. She agreed to start chemotherapy on June 7, which continued weekly for five infusions before she had a hyperbaric breathing emergency and was taken by ambulance to an intensive care unit at a Syracuse hospital. She was at that ICU from July 17 to Aug. 9. "The chemo has failed me. I'm in a very bad place medically,"she wrote in a July 18, 2019 Facebook post. She was given a zero percent chance of survival. Hematology & Oncology Fellow notes July 31, 2019 "Patient has received palliative radiation therapy. 3 daily fractions in addition to one endobronchial brachytherapy ... Keytruda will not be given to an inpatient and patient needs to be more medically stable to be eligible for and tolerate further therapy." In the ICU, Gina was starving and her weight plummeted. A couple of photographs of a gaunt-looking Gina are on the book's back cover. "The reason I put those pictures there is because I was not sick because of cancer, but because of not being treated. It was, 'We are not going to feed the patient because the patient is dying. The patient is dying because she isn't being fed.' One of the reasons I wrote the book is because nobody around me understood the extent of the abuse that was happening, I know without a doubt, had I been able to talk, the entire story would have been different, because I would not have been docile about this happening." Excerpt from Psychological evaluation Aug. 1, 2019 "Patient clearly and persistently repeated ... that she wanted palliative care only rather than aggressive Rx intended to extend life because aggressive Rx was unlikely to work, and hospitalization was so unpleasant." "In retrospect, I had made an almost fatal error," Gina wrote. "I hadn't been willing to lie about my belief in my own death in order to get out." In other words, she said she had to be purposely deceptive to get into Hospice. On Aug. 9, 2019, Gina left the hospital for Hospice care at her North Syracuse home. It was a Friday. "The Hospice coordinator told us that someone would be back in 72 hours," Gina wrote. "She also told Seth I had about three days to live. What excruciating math." Gina received Hospice care for six days, after which she and Seth cut ties with it. Her goal was to return to the home she grew up in, in Watertown. She arrived Aug. 15. Seth carried her into the house. "I knew I was in very bad shape," Gina wrote. "But there was no time for pessimism, and the hard work ahead didn't scare me." At SMC, two weeks after her "two weeks to live," she pleaded to a doctor for a Keytruda prescription. But the doctor would not budge in her refusal. "My temper now getting the best of me, I snarled: 'So, what you're telling me is that you are afraid the Keytruda might kill me before the cancer you know will kill me? Is that the argument? Am I clear on that?' But please, please, just give me a f****** chance to fail. Please don't make the choice for me." The doctor relented. On Aug. 29, 2019, Gina received her first Keytruda infusion. It would be a 30-minute process every three weeks. Two days later, she wrote that her fever subsided. Her lung opened up 15 days later, creating movement in her body, near her rib cage, that was frightening at first. By the second infusion, she was sitting up on her own. She would continue to get stronger, building back every muscle in her body. By late September, Gina was using a walker in her parents' driveway. On Halloween, at her fourth Keytruda infusion at the Walker Cancer Center, Gina saw a nurse that she hadn't seen in over a month. Her book recounts the nurse's reaction: "I watched all the color drain from her face, and she dropped to her knees as she grabbed the cross around her neck. She began to sob right there on the floor. I ran over to comfort her, and she still looked at me as if I were a ghost." Gina believes she could have been given Keytruda on day one, sparing her body the indignity of wasting away. It would have also voided a $2 million ICU stay, she said. Despite being on Medicaid, Gina said she and Seth acquired about $200,000 in medical debt, noting, "living against medical advice isn't covered by Medicaid." They deployed their credit cards, sought financial help from her parents and a GoFundMe drive raised $15,000. "Nobody fights, especially not on Medicaid, because they expect you can't." No cancer, no naïvety Gina's most recent medical appointment reflected being 5 1/2 years cancer free. She is also free from her naïvety relating to medical care. "I think when you see a movie about a severe illness, there's a kind, compassionate, dedicated doctor cheering on the patient, staying up nights to figure out a way, a solution, a plan. I kinda expected that. I miss that naive me. And the patient is stoic, brave, suffering beautifully and angelically. Almost from the day of my diagnosis, I thought of that patient, the Hallmark Heroine. The thing about that woman? She always dies at the end, and people sob because it was so unfair." But that wasn't her fate, or in her nature. "I'd already had 46 years of being cynical, sarcastic and a bit of a jokester. And cancer didn't change that, because I refused to let it own me. To take over, to take away my ability to make fun of any and everything. They say a positive attitude is super beneficial in cancer, but I hope I have shattered that belief." Being "afraid of the world" was also a factor in Gina's cancer battle. "That made it easier to deal with, in a way. It was just another thing to be scared of. I was equally as afraid of going to the hospital, as I was of dying. It absolutely 100 percent saved my life. Without doubt or hesitation. Anxiety teaches you to look for the danger, seek all the exits, and always be prepared to flee. But perhaps above all, avoid situations that feel terrifying. Everything after February 15, 2019 felt out of control, and terrifying. No one in the medical world would have conversations anymore, they only talked at me." The thing about anxiety with PTSD, Gina explained, is that one can become very calm in chaos. "You think clear, sharp and exact. Stillness and boredom are terrifying, but the world blowing up clears the mind. And I think that's why I was able to spot flaws in my treatment plans and question the motivations for them that were nonsensical to me." A key pep talk Despite the medical professionals who "only talked at" Gina and recalled in her book, she also highlighted in her book a few individuals that gave her hope. One was a "Dr. Lee" who was doing a rotation as a hospitalist at SMC, while doing his actual residency at Roswell Park Comprehensive Cancer Center in Buffalo. He now works in Texas. "Dr. Lee was my magic. It's like he came in at the beginning with the best pre-game pep talk, and I followed it the rest of my journey. He was young and didn't have the ego or entitlement I've seen in so many other oncologists I encountered. He was enthusiastic about killing cancer. Stoked. Raring to go. Running into work to kill some cancer!" Gina said that he was also the first and last doctor to root for her. "Which likely sounds odd. But the doctors who saw me get better weren't impressed. It wasn't remarkable to them. They just thought I'd die." The biggest gaping wound Gina said she encountered in oncology was the lack of "heart" she saw in it. "The point is, if there were more Dr. Lee's, I honestly believe more people would survive. Caring spills over into treatment plans, into feeling valued, into a bond of trust, and helps avert not distrusting the doctors, the medicine, the conspiracies." Last month, Gina sent Dr. Lee a copy of her book with a note inside. "And now I feel a bit lighter. It was, in some way, vital for me to let him know how deeply he mattered, that I didn't die, and the part he played in that. And how many fans he has out there in the world now." Helping others As an advocate, Gina said she is contacted nearly every day by people who become familiar with her story. "I'm absolutely thrilled others find something of merit in the book. I didn't want to publish it. It was never my intent. But I felt a deep sense of survivor's guilt, and also I had seen and heard things that might help others avoid some of the unnecessary suffering I endured." Gina said that doctors still regard her as a Stage 4 cancer patient. "The reason is, is that somewhere in my body could be invisible, undetectable, latent cancer cells waiting to come back. The problem with that is that everybody has that. You do, he does," she said, pointing to Seth. I probably don't, because that Keytruda is bad ass!" Her situation is an issue each time she goes to a doctor, "From people being surprised, to the question of whether or not my being screened for other cancers is necessary because, I'm dying." She then laughed, and with well-earned sarcasm added, "I'm always 'dying.' Like, damn! I can't get a break."
Yahoo
25 minutes ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
2 Nasdaq Stocks to Buy in June
Investors could be significantly underestimating Google's artificial intelligence capabilities. Amazon's cloud computing business continues to show monster growth potential. 10 stocks we like better than Alphabet › It's not surprising that the Nasdaq Composite's return of 275% outpaces the S&P 500 return of 178% over the last 10 years. The Nasdaq is full of tech-centric companies that are driving change and innovation in the economy, which is where you'll find stocks with monster growth potential. While the stock market got off to a shaky start this year, there are good opportunities to buy shares of dominant tech firms at attractive valuations. Here are two stocks that can deliver great returns in the coming years. Shares of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) have surged in recent weeks. The company formerly known as Google and home of the famed search engine (among other products) has been weighed down amid increasing competition, fears a recession could slow the advertising market, and the possibility of a court-ordered breakup. But these concerns are well reflected in the stock's modest valuation. Alphabet delivered double-digit growth in revenue and earnings over the last decade. The stock doubled over the last five years and still trades at a modest forward price-to-earnings multiple of 18. That is a bargain for a business with billions of users across popular services like Gmail, YouTube, and Google Search. One of the chief concerns for investors right now is Google's competitive position in search, which generates 56% of the company's revenue. OpenAI's ChatGPT and other leading artificial intelligence (AI) models can function like search engines with a brain, and that is a threat to Google's long-dominant position in the search market. However, Google has very capable AI technology. It built world-class AI infrastructure with a large footprint of data centers, including investment in its Tensor Processing Units (TPUs) for AI workloads. The company also turned heads last fall when it unveiled its Willow chip for quantum computing. The latest version of its Gemini large language model is the top-ranked model on Chatbot Arena's leaderboard at the time of writing. Gemini powers all seven of the company's products with over 2 billion users. These achievements reflect a massive war chest of resources at the company's disposal. Over the last year, Alphabet generated $75 billion in free cash flow on $360 billion of annual revenue, and analysts expect its earnings per share to grow 15% on an annualized basis over the long term. Alphabet's investments in data centers, Gemini, and cloud services are laying the foundation for tremendous growth over the long term. These assets will lead to better services for consumers while also positioning Google to capture a large share of a $1 trillion AI opportunity. These prospects make the stock a compelling buy on the dip. Amazon (NASDAQ: AMZN) stock had a great run over the past few years. Since bottoming out in 2022, the stock soared to new highs, rising 144% and outperforming the Nasdaq's return of 83%. Amazon continues to show solid growth in revenue, while cost reduction efforts in its retail business and growth in cloud computing are helping the business convert more revenue into cool profits. Amazon is in a league of its own when it comes to e-commerce -- its largest business. Revenue from online stores grew 6% year over year in the first quarter to $57 billion, as management saw sales of everyday essentials grow twice as fast as the rest of the business. A healthy number of Prime members are clearly relying on Amazon more, which is strengthening its competitive moat. One of the best reasons to consider buying the stock is Amazon's opportunity in cloud computing. Amazon is making cloud services more cost-effective for businesses with its range of hardware and software solutions. Amazon Web Services currently sits at the top of the $348 billion cloud computing market. Over the last year, it generated $112 billion in revenue, with quarterly revenue up 17% year over year in the first quarter. Amazon's cloud opportunity is massive. It is seeing triple-digit growth for AI services, where it offers tools to help companies build their own AI-based applications. Growing demand for cloud services will significantly grow the value of Amazon's business over the long term, as Amazon Web Services generates most of the company's operating profit. Management believes AWS could generate hundreds of billions in revenue over the long term. Recent demand trends certainly point to AWS becoming a bigger piece of Amazon's business, which is a catalyst for the stock. The stock trades at 33 times trailing earnings. For a business that could see many more years of double-digit earnings growth, Amazon investors could be looking at more market-beating returns. Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and Amazon. The Motley Fool has a disclosure policy. 2 Nasdaq Stocks to Buy in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
